First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Clinical trial NCT05086315 · TERMINATED

Trial details

NCT number: NCT05086315
Sponsor: Sanofi
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Lymphocytic Leukaemia Acute Myeloid Leukaemia Refractory Myelodysplastic Syndromes Blastic Plasmacytoid Dendritic Cell Neoplasia

Start date: 2021-12-08
Primary completion: 2025-06-13
Enrollment: 101

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.